Lannett Company

What Lannett Company does

Lannett Company, Inc. is a US-based generic pharmaceutical manufacturer founded in 1942 and headquartered in Philadelphia, Pennsylvania. The company develops, manufactures, and distributes over 100 unique pharmaceutical product families spanning cardiovascular, central nervous system, anti-infective, analgesic, and respiratory therapeutic categories, across dosage forms including tablets, capsules, oral solutions, elixirs, syrups, inhalation anesthetics, and nasal sprays. Lannett holds 113 FDA-approved ANDAs, operates a 425,000-square-foot cGMP manufacturing facility in Seymour, Indiana with annual capacity of approximately 3.6 billion dosage units, and conducts additional manufacturing across Pennsylvania, New York, Georgia, New Jersey, Kentucky, Alabama, Puerto Rico, Switzerland, and China through Kremers Urban Pharmaceuticals and other subsidiaries.

The company generates revenue primarily through B2B sales to pharmaceutical wholesale distributors, retail pharmacy chains, hospital systems, and specialty pharmacies across the United States, with a dedicated CDMO platform (lannettcdmo.com) providing contract development and manufacturing services to third-party pharmaceutical partners. Lannett has historically specialized in complex generics and non-opioid controlled substance medications, and most recently received FDA approval in May 2026 for LANGLARA, an interchangeable insulin glargine biosimilar co-developed with subsidiary Lanexa Biologics and Sunshine Lake Pharma. The company is publicly traded (NYSE: LCI; OTC: LCNTF) and is currently being acquired by Aurobindo Pharma USA for approximately $250 million on a cash-free, debt-free basis (5.5x EBITDA), with FTC approval received in June 2026 and closing expected before end of June 2026.

Name

Lannett Company

Legal name

Lannett Company, Inc.

Website

https://lannett.com

Company type

Public

Founded year

1942

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Lannett Company is a US generic pharmaceutical manufacturer producing over 100 product families across cardiovascular, CNS, anti-infective, analgesic, and respiratory categories. Founded in 1942, the Philadelphia-based company operates seven US manufacturing facilities and is being acquired by Aurobindo Pharma for $250 million.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210), Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (42345)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Ophthalmic & Otic Generics (HLAIABAF)

akta.pro secondary industry

Respiratory & Allergy Pharmaceuticals (HLAIAAAH)

Keywords

• Generic pharmaceutical manufacturing
• Complex generic drugs
• Controlled substance generics
• CDMO services
• Biosimilar development

Headquarters

HQ city

Philadelphia

HQ country

United States

HQ region

North America

Offices19 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Generic Pharmaceutical Product Sales: Lannett generates revenue through the manufacture and sale of generic pharmaceutical products to pharmacies, healthcare providers, and distribution networks across the United States. The company manufactures over 100 unique pharmaceutical product families spanning multiple therapeutic areas including cardiovascular, central nervous system, anti-infective, analgesic, and respiratory medications. Revenue is generated through direct sales to distributors and healthcare institutions.
2. CDMO (Contract Development and Manufacturing Organization): Lannett offers contract development and manufacturing services through its CDMO platform (lannettcdmo.com), providing manufacturing capabilities to other pharmaceutical companies. This represents an additional revenue stream from third-party manufacturing partnerships.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

Lannett Company develops, manufactures, and distributes generic prescription pharmaceutical products in tablet, capsule, liquid, nasal spray, and inhalation anesthetic dosage forms. The company produces over 100 unique pharmaceutical product families spanning cardiovascular, central nervous system, anti-infective, analgesic, and respiratory therapeutic areas, with 113 FDA-approved ANDAs. Lannett also provides CDMO (Contract Development and Manufacturing Organization) services through a dedicated platform and recently received FDA approval for LANGLARA, an interchangeable insulin glargine biosimilar.

Product overview

Lannett Company is a generic pharmaceutical manufacturer offering a diverse portfolio of over 100 unique pharmaceutical product families across multiple dosage forms including tablets, capsules, liquids, syrups, elixirs, sprays, and inhalation anesthetics. The company's product portfolio spans therapeutic areas such as cardiovascular medications (Verelan PM, Levothyroxine, Mexiletine), central nervous system treatments (Amphetamine Sulfate, Methylphenidate, Oxybutynin), anti-infectives (Azithromycin), and various other therapeutic categories. Lannett also provides CDMO (Contract Development and Manufacturing Organization) services through its dedicated platform, and has recently received FDA approval for LANGLARA, an interchangeable insulin glargine biosimilar developed in partnership with Lanexa Biologics and Sunshine Lake Pharma. Products are manufactured across multiple U.S. facilities in Pennsylvania, Indiana, and New York, with some products also manufactured at international sites.

Differentiator

Problem solved

Functional benefit

Brands

• Kremers Urban Pharmaceuticals: Wholly-owned subsidiary of Lannett Company, originally named Kremers Urban Pharmaceuticals, Inc., home to the Seymour, Indiana manufacturing facility.

Products and services

• Verelan PM Capsules Extended-release verapamil capsules for cardiovascular treatment, available in 100mg, 200mg, and 300mg dosages. Manufactured at Lannett's Gainesville, Georgia facility.
• Azithromycin Tablets Immediate-release azithromycin tablets for antibacterial treatment, available in 250mg and 500mg dosages. Manufactured at Lannett's Dongguan, China facility.
• Oxybutynin Tablets Extended-release oxybutynin chloride tablets for overactive bladder treatment, available in 5mg, 10mg, and 15mg dosages.
• Oxybutynin Syrup Oxybutynin chloride syrup for overactive bladder treatment, 5mg/5mL dosage with raspberry flavor.
• Hyosyne Elixir Hyoscyamine elixir for gastrointestinal disorders, 0.125mg/5mL dosage with lemon flavor.
• Ferrous Sulfate Elixir Ferrous sulfate elixir for iron deficiency anemia treatment, 220mg/5mL with orange-lemon flavor.
• Levorphanol Tartrate Tablets Opioid analgesic tablets for pain management, available in 2mg and 3mg dosages with REMS requirements. Manufactured at East Windsor, New Jersey facility.
• Levothyroxine Tablets Levothyroxine sodium tablets for thyroid hormone replacement, available in multiple strengths from 25mcg to 300mcg. Manufactured at Caguas, Puerto Rico facility.
• Mexiletine Capsules Antiarrhythmic capsules for ventricular arrhythmia treatment, available in 150mg, 200mg, and 250mg dosages. Manufactured at Manno, Switzerland facility.
• Amphetamine Sulfate Tablets Immediate-release amphetamine sulfate tablets for ADHD and narcolepsy treatment, available in 5mg and 10mg dosages. Manufactured at Hoschton, Georgia facility.
• LANGLARA (Insulin Glargine Biosimilar) FDA-approved interchangeable biosimilar referencing Sanofi's Lantus (insulin glargine) for diabetes treatment. Developed jointly by Lannett Company, its subsidiary Lanexa Biologics, and Sunshine Lake Pharma. Can be substituted for Lantus at pharmacies without prescriber intervention in states permitting such substitution.
• CDMO Services Contract development and manufacturing organization services for pharmaceutical products, providing manufacturing capabilities to other pharmaceutical companies for solid and liquid dosage forms through the dedicated platform at lannettcdmo.com.
• Mycophenolate Mofetil for Oral Suspension Mycophenolate mofetil oral suspension (immunosuppressant), 200 mg/mL. Received first-cycle FDA approval, representing a new dosage form for Lannett (powder for oral suspension).

Quantifiable outcome

• 113 approved ANDAs provide substantial regulatory asset base
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered minor and core.

• Quagen Pharmaceuticals LLCminorOthers · 18 June 2026As a condition of FTC approval for Aurobindo Pharma's acquisition of Lannett, Lannett (via Aurobindo) is required to divest four generic drug products to Quagen Pharmaceuticals LLC. The divestiture includes mycophenolate mofetil oral suspension, niacin extended release tablets, pilocarpine tablets, and rabeprazole sodium delayed release tablets. Both Aurobindo and Lannett must provide transition services to enable Quagen to operate the divested assets.
• Lanexa BiologicscoreStrategic or Co-development Partner · 4 May 2026Lannett Company, through its subsidiary Lanexa Biologics, jointly developed LANGLARA (insulin glargine-aldy), an interchangeable biosimilar referencing Sanofi Lantus, with co-development partner Sunshine Lake Pharma. Lannett and Lanexa Biologics intend to pursue broad formulary placement across commercial channels, leveraging each partner's manufacturing and commercialization capabilities.
• Sunshine Lake PharmacoreStrategic or Co-development Partner · 4 May 2026Sunshine Lake Pharma partnered with Lannett Company and its subsidiary Lanexa Biologics to co-develop LANGLARA, an FDA-approved interchangeable insulin glargine biosimilar. Sunshine Lake Pharma leverages its large-scale biologics manufacturing capabilities to supply the US market with the biosimilar product.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Amneal Pharmaceuticals:
• Aurobindo Pharma: Indian pharmaceutical company acquiring Lannett for $250M; one of the largest global generic manufacturers with extensive US presence. The transaction itself highlights direct portfolio and operational overlap between the two companies.

Broad incumbents

• Sandoz (Novartis): Global generic and biosimilar leader with operations in cardiovascular, CNS, anti-infective, and respiratory categories overlapping Lannett's portfolio. CCO Maureen Cavanaugh previously held senior positions at Sandoz.
• Teva Pharmaceutical Industries: World's largest generic drug manufacturer with a broad portfolio across virtually all therapeutic areas where Lannett competes. Multiple Lannett executives (Crew, Cavanaugh, Abt, Brock) previously held senior roles at Teva, making it the most directly comparable peer in scale and portfolio breadth.
• Viatris (formerly Mylan/Upjohn): Large-scale generic pharmaceutical manufacturer with a diversified portfolio across most therapeutic categories and significant US manufacturing presence, directly overlapping Lannett's product and customer footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/lannett-company

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries1 record

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lannett Company